Global Liquid Biopsy Market Overview

Global Liquid Biopsy Market was valued at USD 1.32 billion in 2021 and is expected to reach USD 4.79 billion by the year 2028, at a CAGR of 20.2%.

A liquid biopsy is a simple and non-invasive alternative to surgical biopsies that allows doctors to learn about tumors from a simple blood sample.  In 1994, scientists advanced to the point where they could detect specific mutations in cfDNA. Dennis Lo discovered fetal cfDNA in the blood in 1997, and Veridex released the first commercially available liquid biopsy assay, the CELL SEARCH CTC test, in 2000. The FDA approved the first liquid biopsy test, the Cobas EGFR Mutation Test, as a cfDNA test for the EGFR gene mutation in lung cancer patients' blood in June 2016.

Cancer DNA traces in the blood can indicate which treatments are most likely to be effective for that patient. Liquid biopsy tests capable of detecting epidermal growth factor receptor (EGFR) gene mutations, which occur in 10-35 percent of NSCLC patients, will help doctors choose the best treatment for the right patient at the right time. Although much of the early research on liquid biopsies focused on lung, breast, and prostate cancers, this technology is expected to have a broad impact on all types of cancer. The growing prevalence of cancer patients is expected to stimulate the expansion of the liquid biopsy market over the analyzed timeframe.

Market Dynamics And Factors For Liquid Biopsy Market

Drivers:

Increasing Prevalence of Cancer

Cancer is still one of the leading causes of morbidity and mortality in the world. Cancer is the world's second leading cause of death, according to the WHO. According to the International Agency for Research on Cancer (IARC), the global cancer burden has risen to 19.3 million cases and 9.96 million cancer deaths in 2020. Liquid Biopsy is the emergence of non-invasive cancer diagnostic techniques. The results of a test are typically available much sooner than the results of a standard tissue biopsy. It is possible to make an early diagnosis using liquid biopsy, and the test can be easily repeated if necessary and used as frequently as necessary to monitor the patient's progress. The increasing prevalence of cancer supports the growth of the liquid biopsy market in the forecast period.

Restraints:

Liquid Biopsy Is Not Considered A Typical Testing Procedure

Although liquid biopsy is becoming more popular, tissue biopsy remains the gold standard for disease confirmation and diagnosis, including various cancers, as well as determining disease characteristics. The liquid biopsy test is not currently widely used in the medical community. More clinical trials on the value of liquid biopsies in the medical setting are needed to support the test's clinical utility. Thus, constraining the growth of the market of liquid biopsy during the projected timeframe.

Opportunities:

The Increasing Importance Of Companion Diagnostics

Companion diagnostics are tests or assays that help healthcare providers make treatment decisions for patients based on the best response to therapy. Co-development of companion diagnostics with therapeutic products has the potential to significantly alter the drug development process and accelerate the commercialization of drug candidates by producing safer drugs with improved therapeutic efficacy quickly and cost-effectively. The market for companion diagnostics has a high growth potential due to the increased demand for high-priced specialist therapies and safer drugs. The increasing importance of companion diagnostics is also providing opportunities for growth in the liquid biopsy market. Thus, the future holds a lucrative opportunity for the liquid biopsy market.

Segmentation Analysis Of Liquid Biopsy Market

By cancer type, the lung cancer segment is forecasted to dominate the liquid biopsy market in the upcoming future.  Lung cancer is the most common type of cancer diagnosed through a liquid biopsy. Liquid biopsy is a new technology that could aid in the screening and early detection of lung cancer. There are guidelines and expert recommendations for its use in practice, as well as specific scenarios in which liquid biopsy is actively used. Several biomarkers are currently being studied to obtain important tumor genomic information. The development of targeted therapies has resulted in higher survival rates for patients with advanced non-small-cell lung cancer (NSCLC).

By circulating biomarkers, circulating tumor DNA is expected to be the fastest-growing segment during the forecast period due to the rapid development of next-generation sequencing (NGS) technologies in liquid biopsy advancements applied to circulating tumor DNA (ctDNA). It is thought that the presence of circulating tumor cells (CTCs), which are found in a patient's circulation as rare abnormal cells mixed in with billions of normal red and white blood cells, is required for the development of metastatic cancer. The systems developed for the detection of CTCs have aided in the advancement of cancer treatment.

By End-users, the hospital segment is expected to have the highest share of the liquid biopsy market in the projected timeframe was dominated by the hospital segment. The growth of the liquid biopsy market can be attributed to the increased use of liquid biopsy tests in hospitals and laboratory settings, which are the preferred healthcare facilities for patients.

Regional Analysis Of Liquid Biopsy Market

The North American region is anticipated to have the highest share of the liquid biopsy market in the forecast period due to the growing awareness about the diagnosis of cancer in this region. The large share of this regional segment can be attributed to the ease of access to technologically advanced instruments, the highly developed healthcare systems in the United States and Canada, and the presence of many leading national clinical research laboratories. Cancer affects approximately one in every five Canadians and kills approximately one in every four. In 2021, an estimated 229 200 Canadians will be diagnosed with cancer and 84 600 will die from cancer.

The Europe region is expected to have the second-highest share of the liquid biopsy market in the projected timeframe. European countries are also taking initiatives for the early detection of cancer. For instance, the Innovative Medicines Initiative funded the CANCER-ID project started on 1 January 2015. According to the International Agency for Research on Cancer, there were approximately 19.3 million new cancer cases in 2020, with a 47 percent increase expected by 2040 to reach 28.4 million new cases. As a result, rising cancer diagnosis demand drives global demand for liquid biopsies.

The liquid biopsy market in the APAC region is expected to develop at a significant growth in the projected timeframe. In Southeast Asia in 2020, there will be approximately 159 thousand new cases of breast cancer. In Southeast Asia, there were just over 31 thousand new cases of ovarian cancer in 2020. The OECD and high-income Asia-Pacific countries and territories had high mortality rates among the elderly (70 and older), whereas lower-middle and low-income Asia-Pacific countries and territories had high mortality rates among the young (under 60). For many cancers, the risk of developing the disease increases with age; however, life expectancy in lower-middle and low-income countries and territories is significantly lower than in other countries and territories, so older people die of other diseases.

Covid-19 Impact Analysis On Liquid Biopsy Market

The global pandemic of COVID-19 has slowed the growth rate of the liquid biopsy market from 2020 to 2021. The novel influenza coronavirus (SARS-CoV-2) has disrupted many aspects of our lives, including medical activities. In this setting, much routine cancer diagnostic and therapeutic procedures have been suspended, leading to delays in diagnosis, treatments, and, ultimately, increases in cancer mortality rates. Equally drastic has been the impact of COVID-19 on clinical trials. The pandemic has also impacted the logistics and supplies of cancer diagnostic raw materials and components and other essential commodities utilized in the assembly of liquid biopsy. These factors limit the growth of the liquid biopsy market during the COVID-19 pandemic.

Top Key Players Covered In Liquid Biopsy Market

  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Myriad Genetics Inc. (US)
  • QIAGEN N.V. (Netherlands)
  • Thermo Fisher Scientific Inc. (the US)
  • Guardant Health Inc. (the US)
  • BIOCEPT Inc. (the US)
  • Illumina Inc. (the US)
  • Angle plc (UK)
  • Oncimmune(UK)
  • Lucence health Inc. (US)
  • FreenomeHoldings Inc. (US) and Other Major Players.

Key Industry Development In The Liquid Biopsy Market

In July 2021, Biocept, Inc. was awarded a South Korean Patent for its Primer-Switch technology, which detects rare mutations in circulating tumor DNA (ctDNA) using real-time PCR and associated analysis methods.

In March 2021, Lucence announced a partnership with Waseda University in Japan to develop a unique high-speed liquid biopsy laser-based imaging platform for early cancer detection.

In February 2021, Guardant Health, Inc. announced the supply of Guardant Reveal, the primary blood-only liquid biopsy test for the detection of residual and recurrent disease from an easy blood draw.

Global Liquid Biopsy Market

Base Year:

2021

Forecast Period:

2022-2028

Historical Data:

2016 to 2020

Market Size in 2021:

USD 1.32 Bn.

Forecast Period 2022-28 CAGR:

20.2 %

Market Size in 2028:

USD 4.79 Bn.

Segments Covered:

By Cancer Type

  • Lung
  • Breast
  • Liver
  • Others

By Circulating Biomarker

  • Circulating Tumor DNA
  • Circulating Tumor Cells
  • Others

By End-User

  • Hospitals
  • Laboratories
  • Government Research Centre

By Region

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
  • Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
  • Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
  • South America (Brazil, Argentina, Rest of SA)

Key Market Drivers:

  • Increasing Prevalence of Cancer

Key Market Restraints:

  • Liquid Biopsy Isn’t Yet Considered A Typical Testing Procedure

Key Opportunities:

  • The Increasing Importance Of Companion Diagnostics

Companies Covered in the report:

  • F. Hoffmann-La Roche Ltd. (Switzerland), Myriad Genetics Inc. (US), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific Inc. (the US), Guardant Health Inc. (the US), and Other major players.

Chapter 1: Introduction
 1.1 Research Objectives
 1.2 Research Methodology
 1.3 Research Process
 1.4 Scope and Coverage
  1.4.1 Market Definition
  1.4.2 Key Questions Answered
 1.5 Market Segmentation

Chapter 2:Executive Summary

Chapter 3:Growth Opportunities By Segment
 3.1 By Cancer Type
 3.2 By Circulating Biomarker
 3.3 By End-User

Chapter 4: Market Landscape
 4.1 Porter's Five Forces Analysis
  4.1.1 Bargaining Power of Supplier
  4.1.2 Threat of New Entrants
  4.1.3 Threat of Substitutes
  4.1.4 Competitive Rivalry
  4.1.5 Bargaining Power Among Buyers
 4.2 Industry Value Chain Analysis
 4.3 Market Dynamics
  4.3.1 Drivers
  4.3.2 Restraints
  4.3.3 Opportunities
  4.5.4 Challenges
 4.4 Pestle Analysis
 4.5 Technological Roadmap
 4.6 Regulatory Landscape
 4.7 SWOT Analysis
 4.8 Price Trend Analysis
 4.9 Patent Analysis
 4.10 Analysis of the Impact of Covid-19
  4.10.1 Impact on the Overall Market
  4.10.2 Impact on the Supply Chain
  4.10.3 Impact on the Key Manufacturers
  4.10.4 Impact on the Pricing

Chapter 5: Liquid Biopsy Market by Cancer Type
 5.1 Liquid Biopsy Market Overview Snapshot and Growth Engine
 5.2 Liquid Biopsy Market Overview
 5.3 Lung Cancer
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size (2016-2028F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Lung Cancer: Grographic Segmentation
 5.4 Breast Cancer
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size (2016-2028F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Breast Cancer: Grographic Segmentation
 5.5 Liver Cancer
  5.5.1 Introduction and Market Overview
  5.5.2 Historic and Forecasted Market Size (2016-2028F)
  5.5.3 Key Market Trends, Growth Factors and Opportunities
  5.5.4 Liver Cancer: Grographic Segmentation
 5.6 Others
  5.6.1 Introduction and Market Overview
  5.6.2 Historic and Forecasted Market Size (2016-2028F)
  5.6.3 Key Market Trends, Growth Factors and Opportunities
  5.6.4 Others: Grographic Segmentation

Chapter 6: Liquid Biopsy Market by Circulating Biomarker
 6.1 Liquid Biopsy Market Overview Snapshot and Growth Engine
 6.2 Liquid Biopsy Market Overview
 6.3 Circulating Tumor DNA
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size (2016-2028F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Circulating Tumor DNA: Grographic Segmentation
 6.4 Circulating Tumor Cells
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size (2016-2028F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Circulating Tumor Cells: Grographic Segmentation
 6.5 Other
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size (2016-2028F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Other: Grographic Segmentation

Chapter 7: Liquid Biopsy Market by End-User
 7.1 Liquid Biopsy Market Overview Snapshot and Growth Engine
 7.2 Liquid Biopsy Market Overview
 7.3 Hospitals
  7.3.1 Introduction and Market Overview
  7.3.2 Historic and Forecasted Market Size (2016-2028F)
  7.3.3 Key Market Trends, Growth Factors and Opportunities
  7.3.4 Hospitals: Grographic Segmentation
 7.4 Laboratories
  7.4.1 Introduction and Market Overview
  7.4.2 Historic and Forecasted Market Size (2016-2028F)
  7.4.3 Key Market Trends, Growth Factors and Opportunities
  7.4.4 Laboratories: Grographic Segmentation
 7.5 Government Research Centers
  7.5.1 Introduction and Market Overview
  7.5.2 Historic and Forecasted Market Size (2016-2028F)
  7.5.3 Key Market Trends, Growth Factors and Opportunities
  7.5.4 Government Research Centers: Grographic Segmentation

Chapter 8: Company Profiles and Competitive Analysis
 8.1 Competitive Landscape
  8.1.1 Competitive Positioning
  8.1.2 Liquid Biopsy Sales and Market Share By Players
  8.1.3 Industry BCG Matrix
  8.1.4 Ansoff Matrix
  8.1.5 Liquid Biopsy Industry Concentration Ratio (CR5 and HHI)
  8.1.6 Top 5 Liquid Biopsy Players Market Share
  8.1.7 Mergers and Acquisitions
  8.1.8 Business Strategies By Top Players
 8.2 F. HOFFMANN-LA ROCHE LTD.
  8.2.1 Company Overview
  8.2.2 Key Executives
  8.2.3 Company Snapshot
  8.2.4 Operating Business Segments
  8.2.5 Product Portfolio
  8.2.6 Business Performance
  8.2.7 Key Strategic Moves and Recent Developments
  8.2.8 SWOT Analysis
 8.3 MYRIAD GENETICS INC.
 8.4 QIAGEN N.V.
 8.5 THERMO FISHER SCIENTIFIC INC.
 8.6 GUARDANT HEALTH INC.
 8.7 BIOCEPT INC.
 8.8 ILLUMINA INC.
 8.9 ANGLE PLC.
 8.10 ONCIMMUNE
 8.11 LUCENCE HEALTH INC.
 8.12 FREENOMEHOLDINGS INC.
 8.13 OTHER MAJOR PLAYERS

Chapter 9: Global Liquid Biopsy Market Analysis, Insights and Forecast, 2016-2028
 9.1 Market Overview
 9.2 Historic and Forecasted Market Size By Cancer Type
  9.2.1 Lung Cancer
  9.2.2 Breast Cancer
  9.2.3 Liver Cancer
  9.2.4 Others
 9.3 Historic and Forecasted Market Size By Circulating Biomarker
  9.3.1 Circulating Tumor DNA
  9.3.2 Circulating Tumor Cells
  9.3.3 Other
 9.4 Historic and Forecasted Market Size By End-User
  9.4.1 Hospitals
  9.4.2 Laboratories
  9.4.3 Government Research Centers

Chapter 10: North America Liquid Biopsy Market Analysis, Insights and Forecast, 2016-2028
 10.1 Key Market Trends, Growth Factors and Opportunities
 10.2 Impact of Covid-19
 10.3 Key Players
 10.4 Key Market Trends, Growth Factors and Opportunities
 10.4 Historic and Forecasted Market Size By Cancer Type
  10.4.1 Lung Cancer
  10.4.2 Breast Cancer
  10.4.3 Liver Cancer
  10.4.4 Others
 10.5 Historic and Forecasted Market Size By Circulating Biomarker
  10.5.1 Circulating Tumor DNA
  10.5.2 Circulating Tumor Cells
  10.5.3 Other
 10.6 Historic and Forecasted Market Size By End-User
  10.6.1 Hospitals
  10.6.2 Laboratories
  10.6.3 Government Research Centers
 10.7 Historic and Forecast Market Size by Country
  10.7.1 U.S.
  10.7.2 Canada
  10.7.3 Mexico

Chapter 11: Europe Liquid Biopsy Market Analysis, Insights and Forecast, 2016-2028
 11.1 Key Market Trends, Growth Factors and Opportunities
 11.2 Impact of Covid-19
 11.3 Key Players
 11.4 Key Market Trends, Growth Factors and Opportunities
 11.4 Historic and Forecasted Market Size By Cancer Type
  11.4.1 Lung Cancer
  11.4.2 Breast Cancer
  11.4.3 Liver Cancer
  11.4.4 Others
 11.5 Historic and Forecasted Market Size By Circulating Biomarker
  11.5.1 Circulating Tumor DNA
  11.5.2 Circulating Tumor Cells
  11.5.3 Other
 11.6 Historic and Forecasted Market Size By End-User
  11.6.1 Hospitals
  11.6.2 Laboratories
  11.6.3 Government Research Centers
 11.7 Historic and Forecast Market Size by Country
  11.7.1 Germany
  11.7.2 U.K.
  11.7.3 France
  11.7.4 Italy
  11.7.5 Russia
  11.7.6 Spain
  11.7.7 Rest of Europe

Chapter 12: Asia-Pacific Liquid Biopsy Market Analysis, Insights and Forecast, 2016-2028
 12.1 Key Market Trends, Growth Factors and Opportunities
 12.2 Impact of Covid-19
 12.3 Key Players
 12.4 Key Market Trends, Growth Factors and Opportunities
 12.4 Historic and Forecasted Market Size By Cancer Type
  12.4.1 Lung Cancer
  12.4.2 Breast Cancer
  12.4.3 Liver Cancer
  12.4.4 Others
 12.5 Historic and Forecasted Market Size By Circulating Biomarker
  12.5.1 Circulating Tumor DNA
  12.5.2 Circulating Tumor Cells
  12.5.3 Other
 12.6 Historic and Forecasted Market Size By End-User
  12.6.1 Hospitals
  12.6.2 Laboratories
  12.6.3 Government Research Centers
 12.7 Historic and Forecast Market Size by Country
  12.7.1 China
  12.7.2 India
  12.7.3 Japan
  12.7.4 Singapore
  12.7.5 Australia
  12.7.6 New Zealand
  12.7.7 Rest of APAC

Chapter 13: Middle East & Africa Liquid Biopsy Market Analysis, Insights and Forecast, 2016-2028
 13.1 Key Market Trends, Growth Factors and Opportunities
 13.2 Impact of Covid-19
 13.3 Key Players
 13.4 Key Market Trends, Growth Factors and Opportunities
 13.4 Historic and Forecasted Market Size By Cancer Type
  13.4.1 Lung Cancer
  13.4.2 Breast Cancer
  13.4.3 Liver Cancer
  13.4.4 Others
 13.5 Historic and Forecasted Market Size By Circulating Biomarker
  13.5.1 Circulating Tumor DNA
  13.5.2 Circulating Tumor Cells
  13.5.3 Other
 13.6 Historic and Forecasted Market Size By End-User
  13.6.1 Hospitals
  13.6.2 Laboratories
  13.6.3 Government Research Centers
 13.7 Historic and Forecast Market Size by Country
  13.7.1 Turkey
  13.7.2 Saudi Arabia
  13.7.3 Iran
  13.7.4 UAE
  13.7.5 Africa
  13.7.6 Rest of MEA

Chapter 14: South America Liquid Biopsy Market Analysis, Insights and Forecast, 2016-2028
 14.1 Key Market Trends, Growth Factors and Opportunities
 14.2 Impact of Covid-19
 14.3 Key Players
 14.4 Key Market Trends, Growth Factors and Opportunities
 14.4 Historic and Forecasted Market Size By Cancer Type
  14.4.1 Lung Cancer
  14.4.2 Breast Cancer
  14.4.3 Liver Cancer
  14.4.4 Others
 14.5 Historic and Forecasted Market Size By Circulating Biomarker
  14.5.1 Circulating Tumor DNA
  14.5.2 Circulating Tumor Cells
  14.5.3 Other
 14.6 Historic and Forecasted Market Size By End-User
  14.6.1 Hospitals
  14.6.2 Laboratories
  14.6.3 Government Research Centers
 14.7 Historic and Forecast Market Size by Country
  14.7.1 Brazil
  14.7.2 Argentina
  14.7.3 Rest of SA

Chapter 15 Investment Analysis

Chapter 16 Analyst Viewpoint and Conclusion

Global Liquid Biopsy Market

Base Year:

2021

Forecast Period:

2022-2028

Historical Data:

2016 to 2020

Market Size in 2021:

USD 1.32 Bn.

Forecast Period 2022-28 CAGR:

20.2 %

Market Size in 2028:

USD 4.79 Bn.

Segments Covered:

By Cancer Type

  • Lung
  • Breast
  • Liver
  • Others

By Circulating Biomarker

  • Circulating Tumor DNA
  • Circulating Tumor Cells
  • Others

By End-User

  • Hospitals
  • Laboratories
  • Government Research Centre

By Region

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
  • Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
  • Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
  • South America (Brazil, Argentina, Rest of SA)

Key Market Drivers:

  • Increasing Prevalence of Cancer

Key Market Restraints:

  • Liquid Biopsy Isn’t Yet Considered A Typical Testing Procedure

Key Opportunities:

  • The Increasing Importance Of Companion Diagnostics

Companies Covered in the report:

  • F. Hoffmann-La Roche Ltd. (Switzerland), Myriad Genetics Inc. (US), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific Inc. (the US), Guardant Health Inc. (the US), and Other major players.

LIST OF TABLES

TABLE 001. EXECUTIVE SUMMARY
TABLE 002. LIQUID BIOPSY MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. LIQUID BIOPSY MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. LIQUID BIOPSY MARKET COMPETITIVE RIVALRY
TABLE 005. LIQUID BIOPSY MARKET THREAT OF NEW ENTRANTS
TABLE 006. LIQUID BIOPSY MARKET THREAT OF SUBSTITUTES
TABLE 007. LIQUID BIOPSY MARKET BY CANCER TYPE
TABLE 008. LUNG CANCER MARKET OVERVIEW (2016-2028)
TABLE 009. BREAST CANCER MARKET OVERVIEW (2016-2028)
TABLE 010. LIVER CANCER MARKET OVERVIEW (2016-2028)
TABLE 011. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 012. LIQUID BIOPSY MARKET BY CIRCULATING BIOMARKER
TABLE 013. CIRCULATING TUMOR DNA MARKET OVERVIEW (2016-2028)
TABLE 014. CIRCULATING TUMOR CELLS MARKET OVERVIEW (2016-2028)
TABLE 015. OTHER MARKET OVERVIEW (2016-2028)
TABLE 016. LIQUID BIOPSY MARKET BY END-USER
TABLE 017. HOSPITALS MARKET OVERVIEW (2016-2028)
TABLE 018. LABORATORIES MARKET OVERVIEW (2016-2028)
TABLE 019. GOVERNMENT RESEARCH CENTERS MARKET OVERVIEW (2016-2028)
TABLE 020. NORTH AMERICA LIQUID BIOPSY MARKET, BY CANCER TYPE (2016-2028)
TABLE 021. NORTH AMERICA LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER (2016-2028)
TABLE 022. NORTH AMERICA LIQUID BIOPSY MARKET, BY END-USER (2016-2028)
TABLE 023. N LIQUID BIOPSY MARKET, BY COUNTRY (2016-2028)
TABLE 024. EUROPE LIQUID BIOPSY MARKET, BY CANCER TYPE (2016-2028)
TABLE 025. EUROPE LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER (2016-2028)
TABLE 026. EUROPE LIQUID BIOPSY MARKET, BY END-USER (2016-2028)
TABLE 027. LIQUID BIOPSY MARKET, BY COUNTRY (2016-2028)
TABLE 028. ASIA PACIFIC LIQUID BIOPSY MARKET, BY CANCER TYPE (2016-2028)
TABLE 029. ASIA PACIFIC LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER (2016-2028)
TABLE 030. ASIA PACIFIC LIQUID BIOPSY MARKET, BY END-USER (2016-2028)
TABLE 031. LIQUID BIOPSY MARKET, BY COUNTRY (2016-2028)
TABLE 032. MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET, BY CANCER TYPE (2016-2028)
TABLE 033. MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER (2016-2028)
TABLE 034. MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET, BY END-USER (2016-2028)
TABLE 035. LIQUID BIOPSY MARKET, BY COUNTRY (2016-2028)
TABLE 036. SOUTH AMERICA LIQUID BIOPSY MARKET, BY CANCER TYPE (2016-2028)
TABLE 037. SOUTH AMERICA LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER (2016-2028)
TABLE 038. SOUTH AMERICA LIQUID BIOPSY MARKET, BY END-USER (2016-2028)
TABLE 039. LIQUID BIOPSY MARKET, BY COUNTRY (2016-2028)
TABLE 040. F. HOFFMANN-LA ROCHE LTD.: SNAPSHOT
TABLE 041. F. HOFFMANN-LA ROCHE LTD.: BUSINESS PERFORMANCE
TABLE 042. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 043. F. HOFFMANN-LA ROCHE LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 043. MYRIAD GENETICS INC.: SNAPSHOT
TABLE 044. MYRIAD GENETICS INC.: BUSINESS PERFORMANCE
TABLE 045. MYRIAD GENETICS INC.: PRODUCT PORTFOLIO
TABLE 046. MYRIAD GENETICS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 046. QIAGEN N.V.: SNAPSHOT
TABLE 047. QIAGEN N.V.: BUSINESS PERFORMANCE
TABLE 048. QIAGEN N.V.: PRODUCT PORTFOLIO
TABLE 049. QIAGEN N.V.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 049. THERMO FISHER SCIENTIFIC INC.: SNAPSHOT
TABLE 050. THERMO FISHER SCIENTIFIC INC.: BUSINESS PERFORMANCE
TABLE 051. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
TABLE 052. THERMO FISHER SCIENTIFIC INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 052. GUARDANT HEALTH INC.: SNAPSHOT
TABLE 053. GUARDANT HEALTH INC.: BUSINESS PERFORMANCE
TABLE 054. GUARDANT HEALTH INC.: PRODUCT PORTFOLIO
TABLE 055. GUARDANT HEALTH INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 055. BIOCEPT INC.: SNAPSHOT
TABLE 056. BIOCEPT INC.: BUSINESS PERFORMANCE
TABLE 057. BIOCEPT INC.: PRODUCT PORTFOLIO
TABLE 058. BIOCEPT INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 058. ILLUMINA INC.: SNAPSHOT
TABLE 059. ILLUMINA INC.: BUSINESS PERFORMANCE
TABLE 060. ILLUMINA INC.: PRODUCT PORTFOLIO
TABLE 061. ILLUMINA INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 061. ANGLE PLC.: SNAPSHOT
TABLE 062. ANGLE PLC.: BUSINESS PERFORMANCE
TABLE 063. ANGLE PLC.: PRODUCT PORTFOLIO
TABLE 064. ANGLE PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 064. ONCIMMUNE: SNAPSHOT
TABLE 065. ONCIMMUNE: BUSINESS PERFORMANCE
TABLE 066. ONCIMMUNE: PRODUCT PORTFOLIO
TABLE 067. ONCIMMUNE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 067. LUCENCE HEALTH INC.: SNAPSHOT
TABLE 068. LUCENCE HEALTH INC.: BUSINESS PERFORMANCE
TABLE 069. LUCENCE HEALTH INC.: PRODUCT PORTFOLIO
TABLE 070. LUCENCE HEALTH INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 070. FREENOMEHOLDINGS INC.: SNAPSHOT
TABLE 071. FREENOMEHOLDINGS INC.: BUSINESS PERFORMANCE
TABLE 072. FREENOMEHOLDINGS INC.: PRODUCT PORTFOLIO
TABLE 073. FREENOMEHOLDINGS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 073. OTHER MAJOR PLAYERS: SNAPSHOT
TABLE 074. OTHER MAJOR PLAYERS: BUSINESS PERFORMANCE
TABLE 075. OTHER MAJOR PLAYERS: PRODUCT PORTFOLIO
TABLE 076. OTHER MAJOR PLAYERS: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. LIQUID BIOPSY MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. LIQUID BIOPSY MARKET OVERVIEW BY CANCER TYPE
FIGURE 012. LUNG CANCER MARKET OVERVIEW (2016-2028)
FIGURE 013. BREAST CANCER MARKET OVERVIEW (2016-2028)
FIGURE 014. LIVER CANCER MARKET OVERVIEW (2016-2028)
FIGURE 015. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 016. LIQUID BIOPSY MARKET OVERVIEW BY CIRCULATING BIOMARKER
FIGURE 017. CIRCULATING TUMOR DNA MARKET OVERVIEW (2016-2028)
FIGURE 018. CIRCULATING TUMOR CELLS MARKET OVERVIEW (2016-2028)
FIGURE 019. OTHER MARKET OVERVIEW (2016-2028)
FIGURE 020. LIQUID BIOPSY MARKET OVERVIEW BY END-USER
FIGURE 021. HOSPITALS MARKET OVERVIEW (2016-2028)
FIGURE 022. LABORATORIES MARKET OVERVIEW (2016-2028)
FIGURE 023. GOVERNMENT RESEARCH CENTERS MARKET OVERVIEW (2016-2028)
FIGURE 024. NORTH AMERICA LIQUID BIOPSY MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 025. EUROPE LIQUID BIOPSY MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 026. ASIA PACIFIC LIQUID BIOPSY MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 027. MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 028. SOUTH AMERICA LIQUID BIOPSY MARKET OVERVIEW BY COUNTRY (2016-2028)

Please Wait...

Frequently Asked Questions :

What would be the forecast period in the Liquid Biopsy Market research report?

The forecast period in the Liquid Biopsy Market research report is 2022-2028.

Who are the key players in Liquid Biopsy Market?

F. Hoffmann-La Roche Ltd. (Switzerland), Myriad Genetics Inc. (US), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific Inc. (the US), Guardant Health Inc. (the US), BIOCEPT Inc. (the US), Illumina Inc. (the US), Angle plc (UK), Oncimmune (UK), Lucence health Inc. (US), FreenomeHoldings Inc. (US), and other major players.

What are the segments of the Liquid Biopsy Market?

The Liquid Biopsy Market is segmented into Cancer Type, Circulating Biomarker, End-User, and region. By Cancer Type, the market is categorized into Lung Cancer, Breast Cancer, Liver Cancer, and Others. By Circulating Biomarker, the market is categorized into Circulating Tumor DNA, Circulating Tumor Cells, and Other. By End-User, the market is categorized into Hospitals, Laboratories, and Government Research centers. By region, it is analyzed across North America (U.S.; Canada; Mexico), Europe (Germany; U.K.; France; Italy; Russia; Spain, etc.), Asia-Pacific (China; India; Japan; Southeast Asia, etc.), South America (Brazil; Argentina, etc.), Middle East & Africa (Saudi Arabia; South Africa, etc.).

What is the Liquid Biopsy Market?

A liquid biopsy is a simple and non-invasive alternative to surgical biopsies that allows doctors to learn about tumors from a simple blood sample.  In 1994, scientists advanced to the point where they could detect specific mutations in cfDNA. Dennis Lo discovered fetal cfDNA in the blood in 1997, and Veridex released the first commercially available liquid biopsy assay, the CELL SEARCH CTC test, in 2000. The FDA approved the first liquid biopsy test, the Cobas EGFR Mutation Test, as a cfDNA test for the EGFR gene mutation in lung cancer patients' blood in June 2016.

How big is the Liquid Biopsy Market?

Global Liquid Biopsy Market was valued at USD 1.32 billion in 2021 and is expected to reach USD 4.79 billion by the year 2028, at a CAGR of 20.2%.